Thu, Sep 18, 2014, 8:57 AM EDT - U.S. Markets open in 33 mins.

Recent

% | $
Quotes you view appear here for quick access.

Occidental Petroleum Corporation Message Board

madmoneycramer 262 posts  |  Last Activity: 6 hours ago Member since: Aug 5, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • madmoneycramer madmoneycramer Sep 9, 2014 10:39 AM Flag

    ..Monkeys infected with Ebola five weeks after they were given an ... Glaxo prompts an immune response using a single gene from Ebola

    Sentiment: Strong Buy

  • madmoneycramer madmoneycramer Sep 9, 2014 9:44 AM Flag

    If he sold his options...he may sold some of his holding at 52 weeks high...who would'nt??

    Sentiment: Strong Sell

  • Experimental GSK Ebola Vaccine Creates Immunity in Tests
    Results of Joint Study by Glaxo and U.S. National Institutes of Health Published in Journal Nature Medicine

  • madmoneycramer by madmoneycramer Sep 9, 2014 9:06 AM Flag

    AstraZeneca PLC (AZN.L) -LSE  Follow
    4,587.50 Up +15.50(0.34%) 8:50AM EDT

    Sentiment: Strong Buy

  • We understand that there is a lot of interest amongst our investors to see the shape of the new portfolio that Neil has built for the CF Woodford Equity Income Fund. We commit to disclosing the full portfolio on a monthly basis and aim to do so for the first on 14 July. In the meantime, we are pleased to announce below the top 10 holdings as at 30 June 2014.
    Stock % of portfolio
    AstraZeneca 8.30%
    GlaxoSmithKline 7.11%

  • ..Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE PLC

    Renowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker. Fewer than 1 in 10 of the UK’s top 350 companies earn a place in his funds.

    Hence, I always keep an eye on his holdings for promising investment ideas.

    The following three FTSE 100 firms all currently offer prospective dividend yields of above 5.5%, compared with the FTSE 100 average of 3.3%:

    GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) 1,417p 5.6%
    Centrica (LSE: CNA) (NASDAQOTH: CPYYY) 307p 5.7%
    SSE (LSE: SSE) 1,438 6.2%
    GlaxoSmithKline
    GSK’s shares are trading close to a 52-week low. Allegations of bribery in China, which have hurt sentiment, were already in the public domain when Woodford loaded up on GSK stock for his new fund towards the end of June.

    However, the UK’s top pharma company has since released disappointing half-year results, with competition from generic drugs, some supply-chain problems and adverse currency movements all playing a part. Core earnings are now expected to be flat for the full year (at constant exchange rates).

    Nevertheless, management said “we remain confident in GSK’s medium and long-term growth prospects”. The Board lifted the Q2 dividend (the ex-dividend date is 6 August) by 6%, and analysts’ full-year expectations give a prospective yield of 5.6%.

    Sentiment: Strong Buy

  • madmoneycramer madmoneycramer Sep 9, 2014 8:49 AM Flag

    Great.....look at this....

    3 Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE PLC

    Renowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker. Fewer than 1 in 10 of the UK’s top 350 companies earn a place in his funds.

    Hence, I always keep an eye on his holdings for promising investment ideas.

    The following three FTSE 100 firms all currently offer prospective dividend yields of above 5.5%, compared with the FTSE 100 average of 3.3%:

    GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) 1,417p 5.6%
    Centrica (LSE: CNA) (NASDAQOTH: CPYYY) 307p 5.7%
    SSE (LSE: SSE) 1,438 6.2%
    GlaxoSmithKline
    GSK’s shares are trading close to a 52-week low. Allegations of bribery in China, which have hurt sentiment, were already in the public domain when Woodford loaded up on GSK stock for his new fund towards the end of June.

    However, the UK’s top pharma company has since released disappointing half-year results, with competition from generic drugs, some supply-chain problems and adverse currency movements all playing a part. Core earnings are now expected to be flat for the full year (at constant exchange rates).

    Nevertheless, management said “we remain confident in GSK’s medium and long-term growth prospects”. The Board lifted the Q2 dividend (the ex-dividend date is 6 August) by 6%, and analysts’ full-year expectations give a prospective yield of 5.6%.

  • Reply to

    Tim Cook took profit at $101....and $103

    by shortsp500 Sep 9, 2014 6:43 AM
    madmoneycramer madmoneycramer Sep 9, 2014 8:47 AM Flag

    cannot agree more....Big boys taking profit...Retails will end up in a "LOBSTER'S CAGE" !!!! soon...!!! and trap when stocks goes down.....market correction coming....buy defensive now like Pharma.....like GSK 5.7% yield...or AZN PFE's takeover target

  • Reply to

    AZN should merge with GSK......here why...

    by madmoneycramer Sep 8, 2014 10:03 AM
    madmoneycramer madmoneycramer Sep 9, 2014 6:39 AM Flag

    I know that.....but AZN has the #1 oncology pipeline.....with medimmune in US also...

    GSK is #1 in HIV....will be # 1 in OTC....# 1 in vaccines with NVS deal......also....

  • madmoneycramer madmoneycramer Sep 8, 2014 5:32 PM Flag

    so true....analysts downgrade at 52 weeks low..and upgrade at 52 weeks high...like AAPL....lol

    ...I would love to see if Cramer say "Strong Sell" soon.....You can bet this will be $50 in no time...lol

    Sentiment: Strong Buy

  • Reply to

    PFE Unwise To Seek Inversion

    by snugly60031 Sep 8, 2014 4:39 PM
    madmoneycramer madmoneycramer Sep 8, 2014 5:09 PM Flag

    what about Caymans Islands for corporation America.....and also Banksters???

  • GSK at 52 week low 5.7% yield....

  • at 52 weeks low??? lol

    Sentiment: Strong Buy

  • at 52 week low of $46 level.....!!!

  • madmoneycramer madmoneycramer Sep 8, 2014 1:25 PM Flag

    MedImmune has one of the largest, most robust pipelines in biopharmaceuticals – with a focus on five key areas and over 120 research projects and product candidates in our portfolio.

    MedImmune currently comprises nearly 50% of AstraZeneca's pipeline, and we continue to combine our collective expertise to build a rich, diverse portfolio of small- and large-molecule compounds. This allows us to search for solutions to unmet medical needs, regardless of therapeutic modality.

    Our approach to developing innovative drug candidates is to design and select candidate molecules for optimal biological properties, as well as development properties. This ensures we have the best molecules going forward.

    Our pursuit of innovative drug candidates includes biosuperior products for clinically-validated targets, rather than developing biosimilars intended to copy an original molecule. Biosuperiors are designed to enhance patient value by improving upon an existing product's efficacy, safety profile, route of administration, dosing frequency, or other tangible benefit.

    Download the latest version of the AstraZeneca/MedImmune development pipeline.

    Filter by:
    Phase 1Phase 2Phase 3Submission /
    Approval
    MEDI-565
    Solid Tumors
    MEDI0639
    Solid Tumors
    MEDI0680
    Solid Tumors
    MEDI3617
    Solid Tumors
    MEDI6469
    Solid Tumors
    Moxetumomab Pasudotox
    Leukemia / Lymphoma
    MEDI-551 + Rituximab
    Hematological Malignancies
    MEDI4736 + MEDI0680
    Solid Tumors
    MEDI4736 + Dabrafenib + Trametinib
    Melanoma
    MEDI4736 + IRESSA
    Non-Small Cell Lung Cancer
    MEDI4736 + Tremelimumab
    Solid Tumors
    Tremelimumab + IRESSA
    Non-Small Cell Lung Cancer
    MEDI-551
    Multiple Sclerosis
    MEDI4920
    Primary Sjogren's Syndrome
    MEDI5872
    Systemic Lupus Erythematosus
    MEDI6012
    Arterial Thrombosis
    MEDI8111
    Trauma / Bleeding
    MEDI-550
    Pandemic Influenza Prophylaxis
    MEDI-559
    RSV Prophylaxis
    MEDI4893
    S. aureus Pneumonia
    MEDI7510
    Prevention of RSV in Older Adults
    MEDI8897
    RSV Prophylaxis in Infants
    MEDI1814
    Alzheimer's Disease
    MEDI-551
    Chronic Lymphocytic Leukemia
    MEDI-551
    Diffuse Large B-Cell Lymphoma
    MEDI-573
    Metastatic Breast Cancer
    MEDI2070
    Crohn's Disease
    MEDI7183
    Crohn's Disease
    MEDI7183
    Ulcerative Colitis
    MEDI9929
    Asthma
    Anifrolumab
    Systemic Lupus Erythematosus
    Brodalumab
    Asthma
    Mavrilimumab
    Rheumatoid Arthritis
    Sifalimumab
    Systemic Lupus Erythematosus
    Tralokinumab
    Asthma
    Tralokinumab
    Idiopathic Pulmonary Fibrosis
    MEDI4736
    Non-Small Cell Lung Cancer
    Moxetumomab Pasudotox
    Hairy Cell Leukemia
    Tremelimumab
    Mesothelioma
    Benralizumab
    COPD
    Benralizumab
    Severe Asthma
    Brodalumab
    Psoriasis
    Brodalumab
    Psoriatic Arthritis
    Q-LAIV Flu Vaccine
    Influenza
    Last updated: July 31, 2014

    Sentiment: Strong Buy

  • madmoneycramer madmoneycramer Sep 8, 2014 1:19 PM Flag

    AZN next lung cancer drugs in phase III was recently

    highlight by PFE latest opportunistic attempt..of takeover.....Management is 1500% right......!!

    AZN is on right side of the equation...not Pfizer...lol

    $150-$160B ....way UNDERVALUE now!!!

    Sentiment: Strong Buy

  • Someone wants UK # 1 world vaccines #1 OTC drug in the world #1 Respiratory pharma

    GSK

    AZN is also very nice both with 5% yield....much cheaper than GILD...CELG...AMGN

  • Jim Cramer Says Big Pharma is Thinking Big

    Sentiment: Strong Buy

  • madmoneycramer by madmoneycramer Sep 8, 2014 11:08 AM Flag

    Freaking system....takeover target are getting cheaper for US company....look CELGENE with only $6.5B revenues is $75B value vs GSK or AZN??? Unreal???

OXY
98.17-0.39(-0.40%)Sep 17 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.